What are the standard first-line treatment options for Multiple Myeloma

First-Line Treatment Options for Multiple Myeloma

When you're first diagnosed with active (symptomatic) multiple myeloma, your care team will recommend what's called primary therapy or first-line treatment. This is the initial treatment designed to reduce myeloma cells and control your disease.

How Treatment Decisions Are Made

According to the NCCN Guidelines, the first major decision your team makes is whether you're a candidate for a hematopoietic cell transplant (also called a stem cell transplant). This matters because it affects which drugs are recommended. Your age and overall health status are considered, though importantly, advanced age and kidney problems are NOT automatic reasons to exclude you from transplant eligibility.

Standard Multi-Drug Combinations

The NCCN Guidelines recommend 3-drug or 4-drug combinations (called triplet or quadruplet therapy) as the standard for most patients. These combinations typically include:

• A targeted therapy (proteasome inhibitor)
• An immunomodulator (a drug that helps your immune system fight cancer)
• A monoclonal antibody (an artificial antibody that targets cancer cells)
• A corticosteroid (a steroid medication)

Preferred Combinations for Transplant-Eligible Patients:

According to NCCN Guidelines, preferred options include:

1. Daratumumab + Bortezomib + Lenalidomide + Dexamethasone

   • Daratumumab (monoclonal antibody)
   • Bortezomib (proteasome inhibitor)
   • Lenalidomide (immunomodulator)
   • Dexamethasone (steroid)

2. Isatuximab-irfc + Bortezomib + Lenalidomide + Dexamethasone

   • Isatuximab-irfc (monoclonal antibody)
   • Bortezomib (proteasome inhibitor)
   • Lenalidomide (immunomodulator)
   • Dexamethasone (steroid)

Preferred Combinations for Non-Transplant Candidates:

1. Daratumumab + Lenalidomide + Dexamethasone
2. Isatuximab-irfc + Bortezomib + Lenalidomide + Dexamethasone

Other Recommended Options:

The NCCN Guidelines also list other effective combinations, including those using carfilzomib (another proteasome inhibitor) instead of bortezomib.

What These Drugs Do

Proteasome inhibitors (like bortezomib) block proteins that allow myeloma cells to survive by clearing out waste. When blocked, waste builds up inside cancer cells and destroys them.

Immunomodulators (like lenalidomide) help your immune system recognize and attack cancer cells more effectively.

Monoclonal antibodies (like daratumumab) attach to proteins on myeloma cells and recruit your body's immune cells to destroy them.

Corticosteroids (like dexamethasone) reduce inflammation and help kill cancer cells.

Important Considerations

According to NCCN Guidelines, certain chemotherapy drugs that damage bone marrow (like melphalan) are avoided initially in transplant candidates because they can compromise your ability to collect stem cells later. If you're likely to have a transplant, your team will choose drugs that preserve your stem cell reserve.

What Happens Next

After completing primary therapy (usually 4-6 cycles), your care team will:

• Check how well treatment worked using blood tests and imaging
• Determine if you're ready for a stem cell transplant (if eligible)
• Plan maintenance therapy (lower-dose ongoing treatment) to keep the disease controlled

Questions to Ask Your Care Team

1. Am I a candidate for a hematopoietic cell transplant? (This determines which drugs are best for me)
2. Which specific drug combination do you recommend for my situation, and why?
3. How will we measure if the treatment is working?
4. What are the specific side effects I should watch for with my treatment plan?
5. How often will I have follow-up tests, and what will they measure?
6. If this treatment doesn't work as expected, what are my next options?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.